Is Healthpeak Properties (DOC) Still Undervalued After Raised 2026 Guidance?

Healthpeak Properties has enjoyed a solid share price recovery in recent years, which puts fresh focus on whether the cash generated by its healthcare real estate portfolio is enough to support that move. With the stock now reflecting a long stretch of gains, the real question is how its cash flows stack up against the current price.

• The share price is up 44.2% over the past 3 years, which puts real weight on whether that climb is backed by the cash the business can produce.
• Recent growth in life science and medical office leasing, supported by lab acquisitions and new funding demand from sectors like AI and robotics, may support expectations for stronger and more resilient cash generation from Healthpeak Properties.
• If you'd rather focus on earnings, this one's for you. See why Healthpeak Properties's 37.3x P/E tells a different valuation story.

The issue now is whether Healthpeak Properties' current share price is justified by the cash flows implied by its intrinsic value estimate using a Discounted Cash Flow (DCF) approach.

If you want more ideas built on the same question of whether price lines up with cash flows, a focused screen of 32 high quality undervalued stocks can offer a useful starting list.

Does Healthpeak Properties Look Undervalued on Cash Flow?

The Discounted Cash Flow (DCF) model here is built on Healthpeak Properties' adjusted funds from operations rather than accounting earnings. Over the last twelve months the business produced about $1.29b in free cash flow, and the projections used in the model assume these cash flows keep growing rather than shrinking. That picture supports an intrinsic value outcome that sits substantially above the current share price of $20.38.

Recent news on stronger 2026 guidance and expanding life science leasing helps explain why the cash flow outlook feeding this DCF is framed as recovering rather than flat, even as refinancing risks still hang over future interest costs. Because of that mix of improving operations and funding pressure, the model suggests the market is still pricing Healthpeak Properties below what its projected cash generation implies. Find out what Healthpeak Properties could be worth using our Discounted Cash Flow (DCF) estimate.

The Healthpeak Properties Narrative: What Would Justify Today's Price?

Narratives pick up where the valuation puzzle for Healthpeak Properties' DCF leaves off by explaining which paths for growth, margins and earnings would need to hold for the stock to be worth far more or much less than today’s price, and they sit on Simply Wall St's Community page. Each one treats fair value as a hypothesis about Healthpeak Properties' business that you can watch over time, rather than a single fixed estimate.

Bulls and bears are reading the same Healthpeak Properties updates and coming away with very different conclusions about what the current price reflects.

Bull case: 10% undervalued

The analyst consensus Narrative on Simply Wall St highlights how operating data might give Healthpeak Properties more earnings power than the market credits.

"The accelerating shift of surgical and specialty care from inpatient hospital settings to outpatient centers, supported by Healthpeak Properties reporting roughly 5% cash re leasing spreads for 10 consecutive quarters with about 3% annual rent escalators and low tenant improvements, continues to support stronger same store outpatient NOI and cash flow…"

Discover why this Narrative puts Healthpeak Properties at 10% undervalued.

Bear case: 19% overvalued

The bearish analyst Narrative on Simply Wall St points to refinancing costs and life science exposure as potential brakes on the Healthpeak Properties story.

"Although Healthpeak Properties reports net debt to EBITDA of 4.7x and significant liquidity after repaying US$900 million of debt, the upcoming refinancing of US$650 million of senior notes that carried a roughly 3.5% coupon exposes the company to higher interest costs…"

Explore why this Narrative puts Healthpeak Properties at 19% overvalued.

Healthpeak Properties’ valuation still leaves one powerful variable unresolved

Cash flows and share price only tell part of the story for Healthpeak Properties, because the people setting priorities, approving deals and deciding how rewards are shared with shareholders vs executives can tilt the whole outcome. See who runs Healthpeak Properties and how they are paid.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com